表紙
市場調査レポート

骨粗鬆症:パイプライン製品の分析

Osteoporosis - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 232788
出版日 ページ情報 英文 287 Pages
即納可能
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
骨粗鬆症:パイプライン製品の分析 Osteoporosis - Pipeline Review, H1 2016
出版日: 2016年05月11日 ページ情報: 英文 287 Pages
概要

骨粗鬆症は、骨量の減少により骨の強度が弱まり骨折しやすくなる疾患です。加齢、性別、低体重、性ホルモンの不足または閉経、喫煙、ある種の薬剤による発症のリスクがあります。症状は脊椎の破損や圧迫骨折による腰痛、身長の低下、前屈姿勢、容易な骨折などであり、予防または治療として、カルシウム、ビタミンDの摂取、運動、治療薬による治療が挙げられます。

当レポートでは、骨粗鬆症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

骨粗鬆症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

骨粗鬆症:企業で開発中の治療薬

骨粗鬆症:大学/機関で研究中の治療薬

骨粗鬆症:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

骨粗鬆症:企業で開発中の製品

骨粗鬆症:大学/機関で研究中の製品

骨粗鬆症の治療薬開発に従事している企業

  • Alethia Biotherapeutics Inc.
  • Alize Pharma SAS
  • Alkem Laboratories Ltd.
  • AlphaMab Co., Ltd
  • Amgen Inc.
  • Amura Holdings Limited
  • Arcarios BV
  • BiologicsMD, Inc.
  • Bone Medical Limited
  • Bone Therapeutics SA
  • Caladrius Biosciences, Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Clonz Biotech Private Limited
  • Corium International, Inc.
  • Critical Pharmaceuticals Limited
  • 第一三共
  • ElexoPharm GmbH
  • Eli Lilly and Company
  • EndoCeutics, Inc.
  • Enteris BioPharma, Inc.
  • Enzo Biochem, Inc.
  • Gador S.A.
  • Galapagos NV
  • Glide Pharmaceutical Technologies Limited
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Haoma Medica Ltd.
  • Immunovo BV
  • 科研製薬
  • Korea Kolmar Co. Ltd.
  • Ligand Pharmaceuticals, Inc.
  • Lotus Pharmaceutical Co., Ltd.
  • Merck & Co., Inc.
  • Mereo Biopharma Group Limited
  • Mithra Pharmaceuticals S.A.
  • Novartis AG
  • Omeros Corporation
  • Oncobiologics, Inc.
  • Oscotec Inc.
  • Osteologix Holdings Plc.
  • Paras Biopharmaceuticals Finland Oy
  • PhytoHealth Corporation
  • R-Pharm
  • Radius Health, Inc.
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  • Shin Poong Pharm.Co., Ltd.
  • Sinil Pharmaceutical Co., Ltd
  • STELIS Biopharma Pvt. Ltd.
  • 大日本住友製薬
  • TAmiRNA GmbH
  • TechnoPhage SA
  • Terpenoid Therapeutics, Inc.
  • TSH Biopharm Corporation Limited
  • Uni-Bio Science Group Ltd.
  • Wroclawskie Centrum Badan EIT+ Sp. z o.o.
  • Yooyoung Pharmaceutical Co., Ltd.
  • Zosano Pharma Corporation
  • Zydus Cadila Healthcare Limited

骨粗鬆症:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

骨粗鬆症:最近のパイプライン動向

骨粗鬆症:休止中のプロジェクト

骨粗鬆症:開発が中止された製品

骨粗鬆症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7989IDB

Summary

Global Markets Direct's, 'Osteoporosis - Pipeline Review, H1 2016', provides an overview of the Osteoporosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Osteoporosis
  • The report reviews pipeline therapeutics for Osteoporosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Osteoporosis therapeutics and enlists all their major and minor projects
  • The report assesses Osteoporosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Osteoporosis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Osteoporosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Osteoporosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Osteoporosis Overview
  • Therapeutics Development
    • Pipeline Products for Osteoporosis - Overview
    • Pipeline Products for Osteoporosis - Comparative Analysis
  • Osteoporosis - Therapeutics under Development by Companies
  • Osteoporosis - Therapeutics under Investigation by Universities/Institutes
  • Osteoporosis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Osteoporosis - Products under Development by Companies
  • Osteoporosis - Products under Investigation by Universities/Institutes
  • Osteoporosis - Companies Involved in Therapeutics Development
    • Alethia Biotherapeutics Inc.
    • Alize Pharma SAS
    • Alkem Laboratories Ltd.
    • AlphaMab Co., Ltd
    • Amgen Inc.
    • Amura Holdings Limited
    • Arcarios BV
    • BiologicsMD, Inc.
    • Bone Medical Limited
    • Bone Therapeutics SA
    • Caladrius Biosciences, Inc.
    • Chugai Pharmaceutical Co., Ltd.
    • Clonz Biotech Private Limited
    • Corium International, Inc.
    • Critical Pharmaceuticals Limited
    • Daiichi Sankyo Company, Limited
    • ElexoPharm GmbH
    • Eli Lilly and Company
    • EndoCeutics, Inc.
    • Enteris BioPharma, Inc.
    • Enzo Biochem, Inc.
    • Gador S.A.
    • Galapagos NV
    • Glide Pharmaceutical Technologies Limited
    • Hanmi Pharmaceuticals, Co. Ltd.
    • Haoma Medica Ltd.
    • Immunovo BV
    • Kaken Pharmaceutical Co., Ltd.
    • Korea Kolmar Co. Ltd.
    • Ligand Pharmaceuticals, Inc.
    • Lotus Pharmaceutical Co., Ltd.
    • Merck & Co., Inc.
    • Mereo Biopharma Group Limited
    • Mithra Pharmaceuticals S.A.
    • Novartis AG
    • Omeros Corporation
    • Oncobiologics, Inc.
    • Oscotec Inc.
    • Osteologix Holdings Plc.
    • Paras Biopharmaceuticals Finland Oy
    • PhytoHealth Corporation
    • R-Pharm
    • Radius Health, Inc.
    • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
    • Shin Poong Pharm.Co., Ltd.
    • Sinil Pharmaceutical Co., Ltd
    • STELIS Biopharma Pvt. Ltd.
    • Sumitomo Dainippon Pharma Co., Ltd.
    • TAmiRNA GmbH
    • TechnoPhage SA
    • Terpenoid Therapeutics, Inc.
    • TSH Biopharm Corporation Limited
    • Uni-Bio Science Group Ltd.
    • Wroclawskie Centrum Badan EIT+ Sp. z o.o.
    • Yooyoung Pharmaceutical Co., Ltd.
    • Zosano Pharma Corporation
    • Zydus Cadila Healthcare Limited
  • Osteoporosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (acolbifene hydrochloride + prasterone) - Drug Profile
    • 2-AMD - Drug Profile
    • 2-GES - Drug Profile
    • 3D-QM - Drug Profile
    • 3D-QMS - Drug Profile
    • AB-25E9 - Drug Profile
    • abaloparatide - Drug Profile
    • alendronate sodium - Drug Profile
    • AM-3701 - Drug Profile
    • ARC-205 - Drug Profile
    • blosozumab - Drug Profile
    • BMD-1111 - Drug Profile
    • BN-005 - Drug Profile
    • BN-008 - Drug Profile
    • BPS-804 - Drug Profile
    • calcitonin - Drug Profile
    • CDR-914K058 - Drug Profile
    • CDRI-99/373 - Drug Profile
    • CH-5036249 - Drug Profile
    • denosumab - Drug Profile
    • denosumab biosimilar - Drug Profile
    • denosumab biosimilar - Drug Profile
    • denosumab biosimilar - Drug Profile
    • DPF-020 - Drug Profile
    • Drug to Inhibit miR-31 for Osteoporosis - Drug Profile
    • Drug to Target miR-002 for Osteoporosis - Drug Profile
    • Drugs for Postmenopausal Osteoporosis - Drug Profile
    • Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile
    • DS-1501 - Drug Profile
    • eldecalcitol - Drug Profile
    • Estetrol - Drug Profile
    • Eu-232 - Drug Profile
    • Ewha-18278 - Drug Profile
    • genipin - Drug Profile
    • HCP-1405 - Drug Profile
    • IG-8801 - Drug Profile
    • IHBD-1 - Drug Profile
    • KAL-671 - Drug Profile
    • KKM-0805 - Drug Profile
    • KKM-0902 - Drug Profile
    • KN-012 - Drug Profile
    • lasofoxifene tartrate - Drug Profile
    • MAb-7 - Drug Profile
    • Monoclonal Antibody to Inhibit Sclerostin for Osteoporosis - Drug Profile
    • MOR-106 - Drug Profile
    • NBS-101 - Drug Profile
    • NEP-28 - Drug Profile
    • OCT-1547 - Drug Profile
    • odanacatib - Drug Profile
    • ODS-656 - Drug Profile
    • Oratonin - Drug Profile
    • OXY-149 - Drug Profile
    • PHN-031 - Drug Profile
    • poncirin - Drug Profile
    • PREOB - Drug Profile
    • Proteins to Inhibit RANKL for Oncology and Osteoporosis - Drug Profile
    • R-Spondin 1 - Drug Profile
    • Recombinant Protein 1 for Rheumatoid Arthritis and Osteoporosis - Drug Profile
    • Recombinant Protein 2 for Rheumatoid Arthritis and Osteoporosis - Drug Profile
    • Recombinant Protein 3 for Rheumatoid Arthritis and Osteoporosis - Drug Profile
    • Recombinant Protein for Osteoporosis - Drug Profile
    • Recombinant Protein to Agonize PTH Receptor for Osteoporosis and Osteoarthritis - Drug Profile
    • Recombinant Protein to Inhibit Activin A for Osteoporosis and Cancer Cachexia - Drug Profile
    • Recombinant Protein to Inhibit Serine Protease for Bone Disorders and Osteoporosis - Drug Profile
    • romosozumab - Drug Profile
    • RPH-203 - Drug Profile
    • S-0071500 - Drug Profile
    • S-101479 - Drug Profile
    • S-49288 - Drug Profile
    • SI-000513 - Drug Profile
    • Small Molecule to Agonize LRP for Osteoporosis - Drug Profile
    • Small Molecule to Agonize PTH-1R for Osteoporosis - Drug Profile
    • Small Molecule to Inhibit 17beta-HSD2 for Osteoporosis - Drug Profile
    • Small Molecule to Target LGR4 for Oncology and Osteoporosis - Drug Profile
    • Small Molecule to Target OGR1 for Oncology, Bone Diseases, Asthma and Osteoporosis - Drug Profile
    • Small Molecules for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile
    • Small Molecules for Immunology, Musculoskeletal and Metabolic Disorders - Drug Profile
    • Small Molecules for Osteopenia and Osteoporosis - Drug Profile
    • Small Molecules for Osteoporosis - Drug Profile
    • Small Molecules for Osteoporosis - Drug Profile
    • Small Molecules for Primary Juvenile Osteoporosis - Drug Profile
    • Small Molecules to Agonize Androgen Receptor for Osteoporosis - Drug Profile
    • Small Molecules to Agonize Glucocorticoid Receptor for Osteoporosis - Drug Profile
    • Small Molecules to Inhibit 17Beta-HSD2 for Osteoporosis - Drug Profile
    • Small Molecules to Inhibit GGDPS for Cancer and Bone Metastasis - Drug Profile
    • Small Molecules to Inhibit Kinase for Osteoarthritis and Osteoporosis - Drug Profile
    • Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile
    • Small Molecules to Inhibit Src Tyrosine Kinase for Oncology, Cardiovascular and Metabolic Disorders - Drug Profile
    • Sodium Quinate - Drug Profile
    • SP-35454 - Drug Profile
    • SR-2595 - Drug Profile
    • Stem Cell Therapy for Osteoporosis and Periodontitis - Drug Profile
    • Synthetic Peptide for Osteoporosis - Drug Profile
    • Synthetic Peptide for Osteoporosis and Bone Fracture - Drug Profile
    • T-2GES - Drug Profile
    • teriparatide - Drug Profile
    • teriparatide - Drug Profile
    • teriparatide - Drug Profile
    • teriparatide - Drug Profile
    • teriparatide - Drug Profile
    • teriparatide - Drug Profile
    • teriparatide acetate - Drug Profile
    • teriparatide biosimilar - Drug Profile
    • teriparatide biosimilar - Drug Profile
    • teriparatide biosimilar - Drug Profile
    • teriparatide biosimilar - Drug Profile
    • TZ-121 - Drug Profile
    • Vaccine to Target Sclerostin for Osteoporosis - Drug Profile
    • VS-105 - Drug Profile
    • zoledronic acid - Drug Profile
  • Osteoporosis - Recent Pipeline Updates
  • Osteoporosis - Dormant Projects
  • Osteoporosis - Discontinued Products
  • Osteoporosis - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Osteoporosis, H1 2016
  • Number of Products under Development for Osteoporosis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Osteoporosis - Pipeline by Alethia Biotherapeutics Inc., H1 2016
  • Osteoporosis - Pipeline by Alize Pharma SAS, H1 2016
  • Osteoporosis - Pipeline by Alkem Laboratories Ltd., H1 2016
  • Osteoporosis - Pipeline by AlphaMab Co., Ltd, H1 2016
  • Osteoporosis - Pipeline by Amgen Inc., H1 2016
  • Osteoporosis - Pipeline by Amura Holdings Limited, H1 2016
  • Osteoporosis - Pipeline by Arcarios BV, H1 2016
  • Osteoporosis - Pipeline by BiologicsMD, Inc., H1 2016
  • Osteoporosis - Pipeline by Bone Medical Limited, H1 2016
  • Osteoporosis - Pipeline by Bone Therapeutics SA, H1 2016
  • Osteoporosis - Pipeline by Caladrius Biosciences, Inc. , H1 2016
  • Osteoporosis - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2016
  • Osteoporosis - Pipeline by Clonz Biotech Private Limited, H1 2016
  • Osteoporosis - Pipeline by Corium International, Inc., H1 2016
  • Osteoporosis - Pipeline by Critical Pharmaceuticals Limited, H1 2016
  • Osteoporosis - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Osteoporosis - Pipeline by ElexoPharm GmbH, H1 2016
  • Osteoporosis - Pipeline by Eli Lilly and Company, H1 2016
  • Osteoporosis - Pipeline by EndoCeutics, Inc., H1 2016
  • Osteoporosis - Pipeline by Enteris BioPharma, Inc., H1 2016
  • Osteoporosis - Pipeline by Enzo Biochem, Inc., H1 2016
  • Osteoporosis - Pipeline by Gador S.A., H1 2016
  • Osteoporosis - Pipeline by Galapagos NV, H1 2016
  • Osteoporosis - Pipeline by Glide Pharmaceutical Technologies Limited, H1 2016
  • Osteoporosis - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016
  • Osteoporosis - Pipeline by Haoma Medica Ltd., H1 2016
  • Osteoporosis - Pipeline by Immunovo BV, H1 2016
  • Osteoporosis - Pipeline by Kaken Pharmaceutical Co., Ltd., H1 2016
  • Osteoporosis - Pipeline by Korea Kolmar Co. Ltd., H1 2016
  • Osteoporosis - Pipeline by Ligand Pharmaceuticals, Inc., H1 2016
  • Osteoporosis - Pipeline by Lotus Pharmaceutical Co., Ltd., H1 2016
  • Osteoporosis - Pipeline by Merck & Co., Inc., H1 2016
  • Osteoporosis - Pipeline by Mereo Biopharma Group Limited, H1 2016
  • Osteoporosis - Pipeline by Mithra Pharmaceuticals S.A., H1 2016
  • Osteoporosis - Pipeline by Novartis AG, H1 2016
  • Osteoporosis - Pipeline by Omeros Corporation, H1 2016
  • Osteoporosis - Pipeline by Oncobiologics, Inc., H1 2016
  • Osteoporosis - Pipeline by Oscotec Inc., H1 2016
  • Osteoporosis - Pipeline by Osteologix Holdings Plc., H1 2016
  • Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2016
  • Osteoporosis - Pipeline by PhytoHealth Corporation, H1 2016
  • Osteoporosis - Pipeline by R-Pharm, H1 2016
  • Osteoporosis - Pipeline by Radius Health, Inc., H1 2016
  • Osteoporosis - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2016
  • Osteoporosis - Pipeline by Shin Poong Pharm.Co., Ltd., H1 2016
  • Osteoporosis - Pipeline by Sinil Pharmaceutical Co., Ltd, H1 2016
  • Osteoporosis - Pipeline by STELIS Biopharma Pvt. Ltd., H1 2016
  • Osteoporosis - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016
  • Osteoporosis - Pipeline by TAmiRNA GmbH, H1 2016
  • Osteoporosis - Pipeline by TechnoPhage SA, H1 2016
  • Osteoporosis - Pipeline by Terpenoid Therapeutics, Inc., H1 2016
  • Osteoporosis - Pipeline by TSH Biopharm Corporation Limited, H1 2016
  • Osteoporosis - Pipeline by Uni-Bio Science Group Ltd., H1 2016
  • Osteoporosis - Pipeline by Wroclawskie Centrum Badan EIT+ Sp. z o.o., H1 2016
  • Osteoporosis - Pipeline by Yooyoung Pharmaceutical Co., Ltd., H1 2016
  • Osteoporosis - Pipeline by Zosano Pharma Corporation, H1 2016
  • Osteoporosis - Pipeline by Zydus Cadila Healthcare Limited, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Osteoporosis Therapeutics - Recent Pipeline Updates, H1 2016
  • Osteoporosis - Dormant Projects, H1 2016
  • Osteoporosis - Dormant Projects (Contd..1), H1 2016
  • Osteoporosis - Dormant Projects (Contd..2), H1 2016
  • Osteoporosis - Dormant Projects (Contd..3), H1 2016
  • Osteoporosis - Dormant Projects (Contd..4), H1 2016
  • Osteoporosis - Dormant Projects (Contd..5), H1 2016
  • Osteoporosis - Dormant Projects (Contd..6), H1 2016
  • Osteoporosis - Dormant Projects (Contd..7), H1 2016
  • Osteoporosis - Dormant Projects (Contd..8), H1 2016
  • Osteoporosis - Dormant Projects (Contd..9), H1 2016
  • Osteoporosis - Dormant Projects (Contd..10), H1 2016
  • Osteoporosis - Discontinued Products, H1 2016
  • Osteoporosis - Discontinued Products (Contd..1), H1 2016

List of Figures

  • Number of Products under Development for Osteoporosis, H1 2016
  • Number of Products under Development for Osteoporosis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top